Trial Outcomes & Findings for Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study (NCT NCT01804257)
NCT ID: NCT01804257
Last Updated: 2017-06-16
Results Overview
Comparison of the detection rate of sensor-enabled placebo tablet ingestion using wireless observation (wirelessly observed therapy) to directly observed ingestion. Positive detection accuracy (PDA) for wirelessly observed therapy defined as the number of sensor ingestions detected by wireless observation, divided by the number confirmed ingestions using direct observation. PDA summarized as mean and 95% confidence interval.
COMPLETED
NA
28 participants
4 weeks
2017-06-16
Participant Flow
Participant milestones
| Measure |
Digital Health Feedback System (DHFS)
Ingestion Sensor, Wearable Sensor
Digital Health Feedback System: The digital health offering passively collects and records medication-taking behavior and other habits of daily living
|
|---|---|
|
Overall Study
STARTED
|
28
|
|
Overall Study
COMPLETED
|
27
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Baseline characteristics by cohort
| Measure |
Digital Health Feedback System (DHFS)
n=28 Participants
Ingestion Sensor, Wearable Sensor
Digital Health Feedback System: The digital health offering passively collects and records medication-taking behavior and other habits of daily living
|
|---|---|
|
Age, Customized
|
42.8 years
STANDARD_DEVIATION 12.7 • n=39 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=39 Participants
|
|
Sex: Female, Male
Male
|
18 Participants
n=39 Participants
|
|
Type of Mental Health Disorder
Bipolar Disorder
|
12 Participants
n=39 Participants
|
|
Type of Mental Health Disorder
Schizophrenia
|
16 Participants
n=39 Participants
|
PRIMARY outcome
Timeframe: 4 weeksPopulation: 28 individuals with bipolar disorder (12) or schizophrenia (16)
Comparison of the detection rate of sensor-enabled placebo tablet ingestion using wireless observation (wirelessly observed therapy) to directly observed ingestion. Positive detection accuracy (PDA) for wirelessly observed therapy defined as the number of sensor ingestions detected by wireless observation, divided by the number confirmed ingestions using direct observation. PDA summarized as mean and 95% confidence interval.
Outcome measures
| Measure |
Digital Health Feedback System (DHFS)
n=28 Participants
Ingestion Sensor,...
|
|---|---|
|
Positive Detection Accuracy
|
94 percentage of observed ingestions
Interval 85.4 to 100.0
|
SECONDARY outcome
Timeframe: 8 weeksCharacterize, using summary (descriptive) statistics, the incidence and nature of system-related adverse events (AEs) and serious adverse events (SAEs) that are reported by study investigators over the course of the study
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 4 weeksCharacterize, using summary (descriptive) statistics, medication-taking behavior in free-living environment. Taking adherence defined as the number of ingestion sensors detected by the DHFS in the free-living environment, divided by the prescribed (planned) number of ingestions. Scheduling adherence defined as number of ingestion sensors detected by the DHFS within a ± 2-hour time window around the prescribed (planned) dosing time, divided by the total number of ingestion sensors detected by the DHFS.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 4 weeksCharacterize, using summary (descriptive) statistics, heart rate and rest/activity patterns in a free-living environment. Activity defined as the number of hours per day with recorded a recorded step rate ≥ 60 steps per minute
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 4 weeksCharacterize, using summary (descriptive) statistics, the use of the digital health feedback system and its components by patients, caregivers, and healthcare providers. Use captured utilizing numeric scores collected from a standardized instrument, focusing on overall comfort and ease of DHFS use.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 4 weeksFeedback and suggestions from patients, caregivers, and healthcare providers regarding system metrics and summary presentations of medication-taking, biometrics, and activities of daily living. Feedback includes free text and descriptive statistics summarizing numeric scores collected from a standardized instrument focusing on overall satisfaction with the DHFS and its components.
Outcome measures
Outcome data not reported
Adverse Events
Digital Health Feedback System (DHFS)
Serious adverse events
| Measure |
Digital Health Feedback System (DHFS)
n=28 participants at risk
DHFS
|
|---|---|
|
Psychiatric disorders
schizoaffective disorder
|
3.6%
1/28 • Number of events 1
|
Other adverse events
| Measure |
Digital Health Feedback System (DHFS)
n=28 participants at risk
DHFS
|
|---|---|
|
Skin and subcutaneous tissue disorders
Self-limited rash
|
21.4%
6/28 • Number of events 9
|
Additional Information
John M. Kane MD
Zucker Hillside Hospital, Glen Oaks, NY
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place